Ultragenyx Stock Plummets 40% Following Phase 3 Clinical Trial Failure

Key Facts

1Ultragenyx's experimental drug apazunersen failed to meet primary and secondary endpoints in a Phase 3 trial for Angelman syndrome.

2The company's shares fell 40% in aftermarket trading, bringing its market capitalization to approximately $2.61 billion.

3Evercore ISI downgraded the stock from 'Outperform' to 'In Line' and set a new price target of $16.00.

In a move that underscores the high risks inherent in the biotechnology sector, Ultragenyx Pharmaceutical faced a major setback following the failure of its clinical trials. According to reports, the experimental drug apazunersen failed to meet both primary and secondary endpoints in the Phase 3 Aspire study for Angelman syndrome, as it did not demonstrate the required cognitive improvement. CEO Emil Kakkis expressed disappointment with the results, which directly impact both patient hopes and the company's future growth outlook.

This clinical failure triggered a violent reaction in financial markets, with the company's shares plummeting 40% in aftermarket trading on September 3, 2026. As a result of this sharp decline, the company's market capitalization fell to approximately $2.61 billion. Simultaneously, Evercore ISI downgraded the stock from 'Outperform' to 'In Line' and established a new price target of $16.00, reflecting a significant downward revision from previous expectations.

Based on available data, real-time price levels for the instrument are currently unavailable in the database, but the overall sentiment remains sharply bearish following the trial results. Investors are now watching for further updates from management regarding alternative pipeline strategies, while the economic calendar shows recent stability in US employment data, providing broader market context outside of specific healthcare sector volatility.